Assessment of Cardiovascular Risk in Adults With Type 2 Diabetes and Metabolic Syndrome: Framingham Versus UKPDS Equations

The Diabetes Educator

Volumn 41, Issue 2, 2015, Pages 203-213

  Kim, Chun ja ^a   Kang, Hee Sun ^b   Schlenk, Elizabeth A ^c   Chae, Sun mi ^d  

^a Ajou University   (South Korea)

^b Chung Ang University   (South Korea)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d Seoul National University College of Nursing ^*  (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ANALYSIS; AREA UNDER THE CURVE; BLOOD; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROCEDURES; PROSPECTIVE STUDY; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SOUTH KOREA;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS;

EID: 84926184115     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721715572154     Document Type: Article

References (57)

1. Chan JC, Cho NH, Tajima N, Shaw J. Diabetes in the western pacific region—past, present and future. Diabetes Res Clin Pract. 2014;103:244-255.
2. Rowley WR, Bezold C. Creating public awareness: state 2025 diabetes forecasts. Popul Health Manag. 2012;15:194-200.
3. Kim DJ. The epidemiology of diabetes in Korea. Diabetes Metab J. 2011;35:303-308.
4. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.
5. Ko SH, Kim SR, Kim DJ et al. 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J. 2011;35:431-436.
6. Lau DC, Yan H, Dhillon B. Metabolic syndrome: a marker of patients at high cardiovascular risk. Can J Cardiol. 2006;22(suppl B):85b-90b.
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
8. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629-636.
9. Janszky I, Vatten L, Romundstad P et al. Metabolic syndrome in Poland—the PONS Study. Ann Agric Environ Med. 2011;18:270-272.
10. Szigethy E, Szeles G, Horvath A et al. Epidemiology of the metabolic syndrome in Hungary. Public Health. 2012;126:143-149.
11. Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord. 2009;7:497-514.
12. Pan WH, Yeh WT, Weng LC. Epidemiology of metabolic syndrome in Asia. Asia Pac J Clin Nutr. 2008;17(suppl 1):37-42.
13. Seon CS, Min KW, Lee SY et al. Cardiovascular risk assessment with vascular function, carotid atherosclerosis and the UKPDS risk engine in Korean patients with newly diagnosed type 2 diabetes. Diabetes Metab J. 2011;35:619-627.
14. Kim JH, Kim DJ, Jang HC, Choi SH. Epidemiology of micro- and macrovascular complications of type 2 diabetes in Korea. Diabetes Metab J. 2011;35:571-577.
15. Bonakdaran S, Ebrahimzadeh S, Noghabi SH. Cardiovascular disease and risk factors in patients with type 2 diabetes mellitus in Mashhad, Islamic Republic of Iran. East Mediterr Health J. 2011;17:640-646.
16. Hwang YC, Jee JH, Oh EY et al. Metabolic syndrome as a predictor of cardiovascular diseases and type 2 diabetes in Koreans. Int J Cardiol. 2009;134:313-321.
17. Johnson LW, Weinstock RS. The metabolic syndrome: concepts and controversy. Mayo Clin Proc. 2006;81:1615-1620.
18. Hoerger TJ, Ahmann AJ. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes. J Manag Care Pharm. 2008;14:S2-S14; quiz 15-16.
19. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med. 2006;166:106-111.
20. Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia. 2009;52:2001-2014.
21. D'Agostino RB Sr., Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.
22. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671-679.
23. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care. 2007;30:1292-1293.
24. Davis WA, Colagiuri S, Davis TM. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Med J Aust. 2009;190:180-184.
25. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med. 2005;22:554-562.
26. Kengne AP, Patel A, Colagiuri S et al. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia. 2010;53:821-831.
27. Metcalf PA, Wells S, Scragg RK, Jackson R. Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with type 2 diabetes mellitus. N Z Med J. 2008;121:49-57.
28. Hernaez R, Choque L, Gimenez M, Costa A, Marquez JI, Conget I. [Coronary risk assessment in subjects with type 2 diabetes mellitus. General population-based scores or specific scores?]. Rev Esp Cardiol. 2004;57:577-580.
29. Pellegrini E, Maurantonio M, Giannico IM et al. Risk for cardiovascular events in an Italian population of patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2011;21:885-892.
30. Protopsaltis ID, Konstantinopoulos PA, Kamaratos AV, Melidonis AI. Comparative study of prognostic value for coronary disease risk between the U.K. Prospective Diabetes Study and Framingham models. Diabetes Care. 2004;27:277-278.
31. Zomer E, Liew D, Owen A, Magliano DJ, Ademi Z, Reid CM. Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms. Eur J Prev Cardiol. 2014;21:384-390.
32. International Diabetes Federation. IDF Diabetes Atlas 4th ed. Available at: http://www.idf.org/diabetesatlas/. Accessed April 30, 2012.
33. G*Power [computer program]. Version 3.1.2. Land Nordrhein-Westfalen, Germany: Heinrich-Heine-Universität Düsseldorf; 2010.
34. Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology. 2005;16:73-81.
35. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96:644-647.
36. Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29:1043-1051.
37. Eguchi E, Iso H, Tanabe N et al. Healthy lifestyle behaviours and cardiovascular mortality among Japanese men and women: the Japan Collaborative Cohort Study. Eur Heart J. 2012;33:467-477.
38. Li Y, Sato Y, Yamaguchi N. Lifestyle factors as predictors of general cardiovascular disease: use for early self-screening. Asia Pac J Public Health. 2011;26:414-424.
39. Odegaard AO, Koh WP, Gross MD, Yuan JM, Pereira MA. Combined lifestyle factors and cardiovascular disease mortality in Chinese men and women: the Singapore Chinese health study. Circulation. 2011;124:2847-2854.
40. Orchard TJ, Temprosa M, Goldberg R et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611-619.
41. Kang JY, Cho SW, Sung SH, Park YK, Paek YM, Choi TI. Effect of a continuous diabetes lifestyle intervention program on male workers in Korea. Diabetes Res Clin Pract. 2010;90:26-33.
42. Riediger ND, Clara I. Prevalence of metabolic syndrome in the Canadian adult population. CMAJ. 2011;183:E1127-1134.
43. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva, Switzerland: WHO Press; 2011.
44. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769-1778.
45. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27:2676-2681.
46. Ministry of Health and Welfare of Korea. The Third Report of the Comprehensive Service Program for Healthy Living (2011-2020). Seoul: Ministry of Health and Welfare; 2011.
47. van der Weijden T, van Steenkiste B, Stoffers HE, Timmermans DR, Grol R. Primary prevention of cardiovascular diseases in general practice: mismatch between cardiovascular risk and patients’ risk perceptions. Med Decis Making. 2007;27:754-761.
48. American Diabetes, Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(suppl 1):S11-S61.
49. Lahoz-Rallo B, Blanco-Gonzalez M, Casas-Ciria I et al. Cardiovascular disease risk in subjects with type 2 diabetes mellitus in a population in southern Spain. Diabetes Res Clin Pract. 2007;76:436-444.
50. Shera AS, Jawad F, Maqsood A, Jamal S, Azfar M, Ahmed U. Prevalence of chronic complications and associated factors in type 2 diabetes. J Pak Med Assoc. 2004;54:54-59.
51. Wijesuriya MA, De-Abrew WK, Weerathunga A, Perera A, Vasantharajah L. Association of chronic complications of type 2 diabetes with the biochemical and physical estimations in subjects attending single visit screening for complications. J Diabetology. 2012;2012:3.
52. Damkondwar DR, Raman R, Suganeswari G, Kulothungan V, Sharma T. Assessing Framingham cardiovascular risk scores in subjects with diabetes and their correlation with diabetic retinopathy. Indian J Ophthalmol. 2012;60:45-48.
53. Jurado J, Ybarra J, Solanas P et al. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J Am Acad Nurse Pract. 2009;21:140-148.
54. Park HA, Park JK, Park SA, Lee JS. Age, menopause, and cardiovascular risk factors among Korean middle-aged women: the 2005 Korea National Health and Nutrition Examination Survey. J Womens Health (Larchmt). 2010;19:869-876.
55. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92:1752-1759.
56. McEwan P, Williams JE, Griffiths JD et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med. 2004;21:318-323.
57. Simmons RK, Coleman RL, Price HC et al. Performance of the UK Prospective Diabetes Study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk Cohort. Diabetes Care. 2009;32:708-771.